Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244633 · ClinicalTrials.gov registry record · Phase 1
Ecopipam Treatment of Tourette Syndrome
A Phase 1 study of Tourette's Syndrome, sponsored by Psyadon Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT01244633 is a Phase 1 study of Tourette's Syndrome that has completed, run by Psyadon Pharma. The registered enrollment target is 18 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT01244633, a Phase 1 study of Tourette's Syndrome, has completed, sponsored by Psyadon Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.
Conditions Studied
Interventions
- DRUG Ecopipam
Study Locations (4)
Maryland
- Johns Hopkins University - Baltimore
New Jersey
- Atlantic Neuroscience Institute Overlook Hospital - Summit
New York
- North Shore Hospital - Manhasset
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01244633
The ClinicalTrials.gov registry entry for NCT01244633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Psyadon Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tourette's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ecopipam is the first listed.
NCT01244633 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT01244633 about?
NCT01244633 is a clinical study titled "Ecopipam Treatment of Tourette Syndrome". Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.
What is the current status of trial NCT01244633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-10. Estimated completion is 2013-07.
What conditions does trial NCT01244633 study?
This clinical trial studies the following conditions: Tourette's Syndrome.
What interventions are being tested in trial NCT01244633?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT01244633?
This trial is sponsored by Psyadon Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01244633 being conducted?
This trial has 4 study locations across Maryland, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.